Sugi Predict

Sugi Predict / Compounds / Clavarinone

Clavarinone

Clavarinone

SCHEMBL606233

C[C@H](CCC(O)C(C)(C)O)[C@H]1CC[C@@]2(C)C3=C(CC[C@]12C)[C@@]1(C)C[C@@H](O)C(=O)C(C)(C)[C@@H]1CC3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FNTA P49354 3/20 1.00
▸ FNTB P49356 3/20 1.00
▸ CRYAB P02511 5/20 0.59
▸ CRYAA P02489 1/20 0.54
▸ MAPT P10636 3/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ PLA2G1B P04054 1/20 0.49
▸ DNMT1 P26358 1/20 0.49
▸ BLM P54132 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ ATG4B Q9Y4P1 1/20 0.49
▸ ACHE P22303 2/20 0.49
▸ USP2 O75604 2/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ CYP3A4 P08684 2/20 0.48
▸ ALOX15 P16050 2/20 0.48
▸ LMNA P02545 1/20 0.48
▸ PTGES O14684 1/20 0.46
▸ PREP P48147 1/20 0.46
▸ PIN1 Q13526 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Clavarinone SCHEMBL606234 1.00 FNTA (1.00) FNTAFNTBCRYABCRYAAMAPT
SCHEMBL15934993 0.86 CRYAB (0.78) FNTAFNTBCRYABCRYAAMAPT
Clavaric Acid SCHEMBL8897544 0.83 FNTA (1.00) FNTAFNTBCRYABCRYAAMAPT
Clavaric Acid SCHEMBL3471580 0.83 FNTA (1.00) FNTAFNTBCRYABCRYAAMAPT
SCHEMBL29692186 0.82 CRYAB (0.77) FNTAFNTBCRYABCRYAAMAPT
SCHEMBL17431762 0.82 CRYAB (0.77) FNTAFNTBCRYABCRYAAMAPT
SCHEMBL17428538 0.81 FNTA (0.67) FNTAFNTBCRYABCRYAAMAPT
SCHEMBL5664605 0.77 USP2 (0.73) FNTAFNTBCRYABCRYAAMAPT
SCHEMBL29934605 0.76 FNTA (0.77) FNTAFNTBCRYABCRYAAMAPT
SCHEMBL17428545 0.75 FNTA (0.60) FNTAFNTBCRYABCRYAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1996035707-A1 TERPENOID INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1996-11-14 — — WO claimed
EP-2841109-B1 PRODRUGS OF HYDROXYL-COMPRISING DRUGS ASCENDIS PHARMA AS (DK) 2026-04-15 — — EP disclosed
EP-3782649-B1 BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS ASCENDIS PHARMA AS (DK) 2025-05-14 — — EP disclosed
US-20230381323-A1 RELEASABLE CONJUGATES FISH & RICHARDSON PC 2023-11-30 — — US disclosed
US-11786599-B2 Releasable conjugates QUIAPEG PHARMACEUTICALS AB (SE) 2023-10-17 — — US disclosed
US-20230123784-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels ASCENDIS PHARMA A/S (DK) 2023-04-20 — — US disclosed
EP-4140485-A1 MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV Gilead Sciences, Inc. (US) 2023-03-01 — — EP disclosed
US-11559482-B2 Biodegradable polyethylene glycol based water-insoluble hydrogels ASCENDIS PHARMA A/S (DE) 2023-01-24 — — US disclosed
EP-4011396-A1 RELEASABLE CONJUGATES QuiaPEG Pharmaceuticals AB (SE) 2022-06-15 — — EP disclosed
US-11116774-B2 Modulators of toll-like receptors for the treatment of HIV GILEAD SCIENCES, INC. (US) 2021-09-14 — — US disclosed
WO-2005051452-A2 POLYMER COMPOSITIONS AND METHODS FOR THEIR USE ANGIOTECH INTERNATIONAL AG (CH) 2005-06-09 — — WO disclosed
WO-2005051316-A2 POLYMER COMPOSITIONS AND METHODS FOR THEIR USE ANGIOTECH INTERNATIONAL AG (CH) 2005-06-09 — — WO disclosed
WO-2005046516-A2 MEDICAL IMPLANTS AND ANTI-SCARRING AGENTS ANGIOTECH INTERNATIONAL AG (CH) 2005-05-26 — — WO disclosed
WO-2005018683-A2 ANASTOMOTIC CONNECTOR DEVICES ANGIOTECH INTERNATIONAL AG (CH) 2005-03-03 — — WO disclosed
US-20040225077-A1 Drug delivery from rapid gelling polymer composition ANGIOTECH INTERNATIONAL AG (CH) 2004-11-11 — — US disclosed
US-20040219214-A1 Tissue reactive compounds and compositions and uses thereof ANGIOTECH INTERNATIONAL AG (CH) 2004-11-04 — — US disclosed
WO-2004060346-A2 DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION ANGIOTECH INTERNATIONAL AG (CH) 2004-07-22 — — WO disclosed
WO-2004060405-A2 TISSUE REACTIVE COMPOUNDS AND COMPOSITIONS AND USES THEREOF ANGIOTECH INTERNATIONAL AG (CH) 2004-07-22 — — WO disclosed
US-5703067-A USEFUL IN THE TREATMENT OF CANCER MERCK & CO., INC. (US) 1997-12-30 — — US disclosed
WO-1996035707-A1 TERPENOID INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1996-11-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040219214-A1 Tissue reactive compounds and compositions and uses thereof CD44, SELP, EPCAM FNTA 4500/4885FNTB 4642/4885CRYAB 800/4885
US-11116774-B2 Modulators of toll-like receptors for the treatment of HIV TLR7, TLR3, TLR6 FNTA 3930/4885FNTB 2672/4885CRYAB 4380/4885
US-20230123784-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels PLG, PHYKPL, PLOD3 FNTA 3811/4885FNTB 3931/4885CRYAB 220/4885
US-20230381323-A1 RELEASABLE CONJUGATES GUSB, ABCB11, UGT2B7 FNTA 1134/4885FNTB 1126/4885CRYAB 1540/4885
US-11559482-B2 Biodegradable polyethylene glycol based water-insoluble hydrogels PLG, PHYKPL, PLOD3 FNTA 3811/4885FNTB 3931/4885CRYAB 220/4885
US-11786599-B2 Releasable conjugates GUSB, ABCB11, UGT2B7 FNTA 1134/4885FNTB 1126/4885CRYAB 1540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.